240 related articles for article (PubMed ID: 7688103)
21. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis.
Rops AL; van den Hoven MJ; Bakker MA; Lensen JF; Wijnhoven TJ; van den Heuvel LP; van Kuppevelt TH; van der Vlag J; Berden JH
Nephrol Dial Transplant; 2007 Jul; 22(7):1891-902. PubMed ID: 17550924
[TBL] [Abstract][Full Text] [Related]
22. Expression of platelet-derived growth factor in lupus nephritis in MRL/MpJ-1pr/1pr mice.
Entani C; Izumino K; Takata M; Futamura A; Nakagawa Y; Inoue H; Iida H
Nephron; 1997; 77(1):100-4. PubMed ID: 9380223
[TBL] [Abstract][Full Text] [Related]
23. Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
Tan H; Zhao J; Wang S; Zhang L; Wang H; Huang B; Liang Y; Yu X; Yang N
Int Immunopharmacol; 2012 Dec; 14(4):401-9. PubMed ID: 22922317
[TBL] [Abstract][Full Text] [Related]
24. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
26. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.
Hasegawa H; Kohno M; Sasaki M; Inoue A; Ito MR; Terada M; Hieshima K; Maruyama H; Miyazaki J; Yoshie O; Nose M; Fujita S
Arthritis Rheum; 2003 Sep; 48(9):2555-66. PubMed ID: 13130475
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice.
Zhao C; Gu Y; Chen L; Su X
Int Immunopharmacol; 2020 Dec; 89(Pt A):107027. PubMed ID: 33039957
[TBL] [Abstract][Full Text] [Related]
28. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice.
Woo J; Wright TM; Lemster B; Borochovitz D; Nalesnik MA; Thomson AW
Clin Exp Immunol; 1995 Apr; 100(1):118-25. PubMed ID: 7535208
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice].
Ding ZX; Yang SF; Wu QF; Lu Y; Chen YY; Nie XL; Jie HY; Qi JM; Wang FS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Apr; 31(4):656-60. PubMed ID: 21515463
[TBL] [Abstract][Full Text] [Related]
30. Iron status alters murine systemic lupus erythematosus.
Leiter LM; Reuhl KR; Racis SP; Sherman AR
J Nutr; 1995 Mar; 125(3):474-84. PubMed ID: 7876923
[TBL] [Abstract][Full Text] [Related]
31. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
32. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
33. Studies on the mechanisms of the development of lupus nephritis in BXSB mice. II. Comparative studies between male BXSB and MRL/lpr mice at the onset period.
Makino M; Fujiwara M; Watanabe H
J Clin Lab Immunol; 1988 Feb; 25(2):83-8. PubMed ID: 3259631
[TBL] [Abstract][Full Text] [Related]
34. Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis.
Kim CS; Mathew AP; Vasukutty A; Uthaman S; Joo SY; Bae EH; Ma SK; Park IK; Kim SW
J Nanobiotechnology; 2021 Apr; 19(1):109. PubMed ID: 33865397
[TBL] [Abstract][Full Text] [Related]
35. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
Bao L; Haas M; Boackle SA; Kraus DM; Cunningham PN; Park P; Alexander JJ; Anderson RK; Culhane K; Holers VM; Quigg RJ
J Immunol; 2002 Apr; 168(7):3601-7. PubMed ID: 11907125
[TBL] [Abstract][Full Text] [Related]
36. Complement factor H deficiency accelerates development of lupus nephritis.
Bao L; Haas M; Quigg RJ
J Am Soc Nephrol; 2011 Feb; 22(2):285-95. PubMed ID: 21148254
[TBL] [Abstract][Full Text] [Related]
37. 1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-κB and MAPK signalling pathways in MRL/lpr mice.
Li X; Liu J; Zhao Y; Xu N; Lv E; Ci C; Li X
BMC Nephrol; 2022 Jul; 23(1):243. PubMed ID: 35804318
[TBL] [Abstract][Full Text] [Related]
38. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice.
Sekine H; Watanabe H; Gilkeson GS
J Immunol; 2004 Mar; 172(6):3913-21. PubMed ID: 15004199
[TBL] [Abstract][Full Text] [Related]
39. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice.
Inoue A; Hasegawa H; Kohno M; Ito MR; Terada M; Imai T; Yoshie O; Nose M; Fujita S
Arthritis Rheum; 2005 May; 52(5):1522-33. PubMed ID: 15880599
[TBL] [Abstract][Full Text] [Related]
40. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF.
Ji J; Xu J; Li F; Li X; Gong W; Song Y; Dou H; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):411-9. PubMed ID: 27121231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
